Emmaus Life Sciences, Inc.
EMMA
$0.01
$0.00-1.02%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -41.78% | -29.92% | -34.70% | -43.73% | -28.22% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -41.78% | -29.92% | -34.70% | -43.73% | -28.22% |
| Cost of Revenue | -14.04% | 19.38% | -0.09% | -10.51% | -39.70% |
| Gross Profit | -43.33% | -32.26% | -36.38% | -45.31% | -27.45% |
| SG&A Expenses | -39.53% | -28.61% | -29.64% | -29.06% | -23.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -38.16% | -27.32% | -28.64% | -28.82% | -26.30% |
| Operating Income | -4,150.00% | -39.41% | -106.82% | -153.50% | -97.65% |
| Income Before Tax | -103.35% | 25.24% | 7.38% | -69.41% | 23.28% |
| Income Tax Expenses | 98.88% | -1,062.00% | 134.78% | 149.15% | -228.99% |
| Earnings from Continuing Operations | -108.50% | 35.58% | 4.21% | -72.86% | 26.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -108.50% | 35.58% | 4.21% | -72.86% | 26.28% |
| EBIT | -4,150.00% | -39.41% | -106.82% | -153.50% | -97.65% |
| EBITDA | -1,807.32% | -41.70% | -105.67% | -152.41% | -94.91% |
| EPS Basic | -110.31% | 35.01% | 9.00% | -39.06% | 41.23% |
| Normalized Basic EPS | -66.32% | 18.68% | 22.15% | -104.12% | 14.99% |
| EPS Diluted | -103.42% | 33.29% | 8.71% | -36.44% | 37.27% |
| Normalized Diluted EPS | -66.32% | 27.05% | 30.25% | -76.14% | 24.15% |
| Average Basic Shares Outstanding | 4.59% | 9.16% | 14.06% | 19.09% | 18.12% |
| Average Diluted Shares Outstanding | 4.59% | -19.86% | -17.29% | -14.87% | -16.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |